Irsogladine is a potent inhibitor of angiogenesis.
We describe a novel inhibitor of angiogenesis, Irsogladine, an anti-ulcer drug. Irsogladine inhibited plasminogen activator synthesis of, and tube formation by, human microvascular endothelial cells in type 1 collagen gel treated with an angiogenic growth factor, EGF. Furthermore, Irsogladine administered orally significantly inhibited in vivo angiogenesis in mice. Irsogladine may be useful in the treatment of diseases associated with angiogenesis.
Sato
Y
Y
Department of Internal Medicine 1, Oita Medical University, Japan.
Morimoto
A
A
Kiue
A
A
Okamura
K
K
Hamanaka
R
R
Kohno
K
K
Kuwano
M
M
Sakata
T
T
D000818:Animals; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000201:enzymology; D004790:Enzyme Induction / Q000187:drug effects; D006801:Humans; D051379:Mice; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000187:drug effects*; D014227:Triazines / Q000494:pharmacology*
D014227:Triazines; D010959:Tissue Plasminogen Activator; C041836:irsogladine